

Carl Lint

Robert J. Collins
Robert J. Lukes

Concordance of the Kiel and Lukes-Collins classifications of non-Hodgkin's lymphomas




Obituary – Professor Dr. Robert J. Lukes

Ann Hematol (1995) 71:103


From 1972 on, Dr. Lukes and his colleague Dr. Robert Collins shared a basic idea with the Kiel group, namely that of deriving malignant lymphomas from the immunologically defined types of lymphocytes. Thus the so-called Lukes-Collins classification and the Kiel classification evolved simultaneously, the latter introduced by the European Lymphoma Club.

The 1970's were very exciting but tumultuous times – not everyone was on the same page!



“It was the best of times,
it was the worst of times,
it was the age of wisdom,
it was the age of
foolishness....”

The 1970's were very exciting but tumultuous times – not everyone was on the same page!



“It was the best of times,
it was the worst of times,
it was the age of wisdom,
it was the age of
foolishness....”

CLASSIFICATION OF NON-HODGKIN'S LYMPHOMAS

SIR,—The announcement in *The Lancet* (Aug. 17, pp. 405–408) of two more classifications of non-Hodgkin's lymphomas encourages me to put forward my classification of these classifications:

Well-defined, high-grade, oligosyllabic

Poorly differentiated, polysyllabic

- diffuse
- circumlocutory
- with dyslexogenesis

Unicentric

- derivative
- neologistic

Multicentric, cycnophilic (Gk. κυκνος = swan)

Cleaved and convoluted types

- Rappaport (non-Lukes)
- Lukes (non-Rappaport)

This system makes no claim to be comprehensive or even comprehensible, so there may well be scope for other classifications of classifications and ultimately, one hopes, a classification of classifications of classifications. At that point we shall need a conference in the Caribbean.

Royal Marsden Hospital,
Fulham Road,
London SW3 6JJ.

H. E. M. KAY.

Lancet
1974

7;2(7880):
586

CLASSIFICATION OF NON-HODGKIN'S LYMPHOMAS

SIR,—The announcement in *The Lancet* (Aug. 17, pp. 405–408) of two more classifications of non-Hodgkin's lymphomas encourages me to put forward my classification of these classifications:

Well-defined, high-grade, oligosyllabic

Poorly differentiated, polysyllabic

- diffuse
- circumlocutory
- with dyslexogenesis

Unicentric

- derivative
- neologistic

Multicentric, cycnophilic (Gk. κυκνος = swan)

Cleaved and convoluted types

- Rappaport (non-Lukes)
- Lukes (non-Rappaport)

This system makes no claim to be comprehensive or even comprehensible, so there may well be scope for other classifications of classifications and ultimately, one hopes, a classification of classifications of classifications. At that point we shall need a conference in the Caribbean.

Royal Marsden Hospital,
Fulham Road,
London SW3 6JJ.

H. E. M. KAY.

Lancet
1974

7;2(7880):
586

1980s

CELEBRATE THE CENTURY®

HISTORICAL EVENTS • TECHNOLOGY • ENTERTAINMENT • SCIENCE

ART • SPORTS • LIFE STYLES



Space Shuttle Launched, Berlin Wall Falls

The space shuttle Columbia, the first reusable space shuttle, was originally launched April 12, 1981. Sandra Day O'Connor became the first female Justice on the U.S. Supreme Court, and Sally Ride became the first American woman in space. The Iran-Contra hearings made headlines.

Several events signaled the easing of international tensions. In December 1987 President Ronald Reagan and Soviet leader Mikhail Gorbachev signed a nuclear arms reduction treaty. The fall of the Berlin Wall in November 1989 presaged the end of the Cold War.

The Vietnam Veterans Memorial was dedicated November 13, 1982. A new national holiday, Martin Luther King Day, was first celebrated in January 1986.


The growth of cable television, video games, and compact discs had a major impact on home entertainment. Dallas and The Cosby Show topped TV ratings. Hip-hop culture and music videos gained popularity.

New Words: yuppie, infomercial, biodegradable



NCI Working Formulation

Cancer 49:2112, 1982



Morphologic classification based in large part on survival data from the late 1970s.

Some felt the Working Formulation was dead on arrival while others rallied behind it, but with growing perceptions of a continental divide, other classifications aging, and the need for an up-to-date biologically meaningful & clinically useful classification,




Enter the International Lymphoma Study Group (ILSG)

VOL 84, NO 5

SEPTEMBER 1, 1994

BLOOD

Journal of the American Society of Hematology



Pathology of Lymphomas (see page 1361)

American Society of Hematology
Thirty-Sixth Annual Meeting
December 2-6, 1994
Nashville, TN

W. B. SAUNDERS COMPANY
A DIVISION OF
HARCOURT BRACE & COMPANY

PERSPECTIVE

A Revised European-American Classification of Lymphoid Neoplasms: A Proposal From the International Lymphoma Study Group

By Nancy Lee Harris, Elaine S. Jaffe, Harald Stein, Peter M. Banks, John K.C. Chan, Michael L. Cleary, Georges Delsol, Christine De Wolf-Peeters, Brunangelo Falini, Kevin C. Gatter, Thomas M. Grogan, Peter G. Isaacson, Daniel M. Knowles, David Y. Mason, Hans-Konrad Muller-Hermelink, Stefano A. Pileri, Miguel A. Piris, Elisabeth Ralfkjaer, and Roger A. Warnke

THE HISTOLOGIC categorization of lymphoma has been a source of frustration for many years for both clinicians and pathologists. In the last 10 years, much new information has become available about the lymphomas, resulting in recognition of new entities and refinement of previously recognized disease categories. Using the nomenclature of the World Health Organization for new lymphoma classification, in this paper we report the results of an international study of lymphomas, which we hope may clarify some of the confusion surrounding this topic.

This review was conducted at a meeting of 19 hematopathologists with particular interest and experience in lymphomas (the International Lymphoma Study Group) in Berlin, Germany, in April 1993. At previous meetings in Europe and the United States, we had come to believe that, despite the variety of classification schemes used, many hematopathologists appeared to agree on a rather large number of distinct lymphoma entities that they recognize and diagnose in daily practice. We believed that we could provide a useful service to both pathologists and clinicians by reaching a consensus regarding the categories of lymphoid neoplasia that can be reliably recognized at present.

What emerged from this meeting was, first, that each of us had independently evolved ways of viewing these diseases that were essentially identical. Surprisingly, there was little divergence between European and US participants. Second, it was evident that, while many of these lymphoma entities are well defined, others are not. Classification systems often ignore the variable nature of these diseases. Furthermore, there are many differences in how both the pathologist and the clinician view certain subtypes of lymphoma in these items. We have found that we can distinguish categories that are easy to recognize, others that are easily prone to subjective variability. This feature of lymphoma diagnosis has not been emphasized in previous schemes for classification, which imply that all categories are equally easy for the pathologist to recognize.

Ideally, lymphoma, like most other tumors, should be classified into entities that are clinically relevant. This is not always possible. Thus, it is important to be informed about disease course and history in order to propose treatment regimens. It is also important to understand the lymphoid compartments in humans and movement of cells between these compartments still contains many uncertainties. Furthermore, there are difficulties in defining the full extent of the neoplastic clone in individual cases of lymphoma, and some well-defined lymphoma types lack obvious normal counterparts. Consequently, although differentiation schemes provide useful conceptual frameworks for

understanding lymphomas and suggest important new lines of research, our current understanding of both the immune system and the lymphomas appears to be inadequate to support a biologically "correct" lymphoma classification. Thus, a classification strictly based on a theoretical relationship of one entity to another based on stages of differentiation is both unusual and unnecessary for the practical categorization of human lymphomas.

We believe that the most practical approach to lymphoma classification at this time is simply to define the entities that we think we can recognize with the currently available morphologic, immunologic, and genetic techniques.¹ Thus, a lymphoma classification becomes simply a list of well-defined, "real" disease entities. Many of these entities are associated with distinctive clinical presentations and natural histories, even though treatment options may be limited. Cases that do not fit into one of these defined entities are best left unclassified, reflecting the fact that we do not yet understand everything about lymphomas or the immune system.

In this article, we summarize the entities agreed on at the meeting, give the major defining histologic, immunologic, and genetic features, their clinical presentations and course, and postulated normal counterpart in the immune system. It is obviously impossible in this space to cover all diseases completely, and more detailed descriptions of most of these entities are available in the literature. Thus, we have focused

Table 1. List of Lymphoid Neoplasms Recognized by the International Lymphoma Study Group

- B-Cell Neoplasms**
- I. Precursor B-cell neoplasm: Precursor B-lymphoblastic leukemia/lymphoma
 - II. Peripheral B-cell neoplasms
 1. B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma
 2. Lymphoplasmacytoid lymphoma/immunocytoma
 3. Mantle cell lymphoma
 4. Follicular center lymphoma, follicular Provisional cytologic grades: I (small cell), II (mixed small and large cell), III (large cell)
Provisional subtype: diffuse, predominantly small cell type
 5. Marginal zone B-cell lymphoma
Extranodal (MALT-type +/- monocytoid B cells)
Provisional subtype: Nodal (+/- monocytoid B cells)
 6. Provisional entity: Splenic marginal zone lymphoma (+/- villous lymphocytes)
 7. Hairy cell leukemia
 8. Plasmacytoma/plasma cell myeloma
 9. Diffuse Large B-cell lymphoma*
Subtype: Primary mediastinal (thymic) B-cell lymphoma
 10. Burkitt's lymphoma
 11. Provisional entity: High-grade B-cell lymphoma, Burkitt-like*

T-Cell and Putative NK-Cell Neoplasms

- I. Precursor T-cell neoplasm: Precursor T-lymphoblastic lymphoma/leukemia
- II. Peripheral T-cell and NK-cell neoplasms
 1. T-cell chronic lymphocytic leukemia/prolymphocytic leukemia
 2. Large granular lymphocyte leukemia (LGL)
T-cell type
NK-cell type
 3. Mycosis fungoides/Sézary syndrome
 4. Peripheral T-cell lymphomas, unspecified*
Provisional cytologic categories: medium-sized cell, mixed medium and large cell, large cell, lymphoepithelioid cell
Provisional subtype: Hepatosplenic $\gamma\delta$ T-cell lymphoma
Provisional subtype: Subcutaneous panniculitic T-cell lymphoma
 5. Angioimmunoblastic T-cell lymphoma (AILD)
 6. Angiocentric lymphoma
 7. Intestinal T-cell lymphoma (+/- enteropathy associated)
 8. Adult T-cell lymphoma/leukemia (ATLL)
 9. Anaplastic large cell lymphoma (ALCL), CD30*, T- and null-cell types
 10. Provisional entity: Anaplastic large-cell lymphoma, Hodgkin's-like

Hodgkin's Disease

- I. Lymphocyte predominance
- II. Nodular sclerosis
- III. Mixed cellularity
- IV. Lymphocyte depletion
- VI. Provisional entity: Lymphocyte-rich classical HD

* These categories are thought likely to include more than one disease entity.

R.E.A.L.
classification